Marijuana.com.au (Page 2)

What would legal cannabis really earn Victoria?

We ran the numbers..

SMH reports Fair Work Commission upheld dismissal of Newcastle researcher who led cannabinoid studies

The Sydney Morning Herald reported that a Fair Work Commission full bench rejected a University of Newcastle professor's appeal against his dismissal over consent failures in research that included a cannabinoid partnership with Ecofibre.

Health care safety commission reports no high-quality evidence for medicinal cannabis as a first-line option

The Australian Commission on Safety and Quality in Health Care has published a report for clinicians summarising systematic reviews of medicinal cannabis evidence from 2020 to 2025.

DVA responds to Four Corners 'Defenceless' investigation, citing changes to its Medicinal Cannabis Framework

The Department of Veterans' Affairs said in a 6 October statement responding to Four Corners' "Defenceless" that it has updated its Medicinal Cannabis Framework, including requiring initial GP consultations.

ECS Botanics announces UK distribution and manufacturing agreement with Curaleaf Laboratories

ECS Botanics Holdings told the ASX on 7 October 2026 it has entered a distribution and manufacturing agreement with Curaleaf Laboratories for ECS-branded medicinal cannabis in the UK.

TGA publishes guidance on when news reporting about therapeutic goods may be advertising

The TGA said on 29 September it has published guidance explaining when news content about therapeutic goods may be regulated as advertising.

SBS reports online prescriber MOCA removed inaccurate regulatory-status claim from its website

SBS News reported that Medicinal Organic Cannabis Australia removed a website statement about its products' approval status after the broadcaster's inquiries.

ABC reports on DVA-funded medicinal cannabis prescribing to veterans through for-profit providers

ABC News reported that a veteran was prescribed very high THC doses through DVA-funded for-profit providers, and that DVA has since tightened its rules.

How a Soft Diagnosis Becomes a Hard Headline

Two of eleven. That's the entire bar for a diagnosis now making headlines as "cannabis addiction."

New Genetics Study Splits "Cannabis Use" From "Cannabis Use Disorder"

Roughly one in ten people who try cannabis goes on to develop cannabis use disorder (CUD). What separates that minority from everyone else who uses cannabis without it becoming a problem has never been well understood.

The Chronic Illness Trap: Why NSW’s New Medical Cannabis Driving Laws Are a Backdoor Ban

These changes do not liberate medicinal cannabis users; instead, they establish a digital surveillance framework that explicitly targets and bans people with chronic illnesses from driving.

The Study Said Psychosis Rates Were Equal to Placebo. Most Outlets Left That Part Out.

A major Lancet Psychiatry meta-analysis on cannabinoids and mental health was reported accurately on some points, incompletely on others, and misleadingly on at least one finding that cuts against a well-established media narrative. Often, all three occurred in the same article.`

Running on Empty: Why Hemp Derived Biodiesel Deserves a Serious Place in Australia's Fuel Future

"Australia cannot refinery-build its way out of this crisis quickly enough. But it can grow its way toward a more resilient position — if it chooses to."

New Preclinical Research Explores the Endocannabinoid System in Alzheimer's Disease and Chronic Pain

The endocannabinoid system plays a modulatory role in both pain processing and neurological function. It is altered in both Alzheimer's disease and chronic pain states, making it an area of active research interest.

Two Veterans, Same Diagnosis, Different Rules: DVA's New Medicinal Cannabis Framework Creates a Two-Tier System

For a veteran in outback Queensland newly diagnosed with a terminal illness, "find a specialist and attend in person first" is not a neutral administrative requirement. It is a genuine barrier to care, arriving at the worst possible time.

Cannabis Shows Promise for Advanced Pancreatic Cancer Symptom Management

The study was supported by philanthropic funding to the HealthPartners Cancer Research Centre, with cannabis products provided by Vireo Health (GreenGoods, Minnesota).

Legalise Cannabis Australia

Victorian Medicinal Cannabis Driving Trial Reaches Key Milestone

Recruitment of adults with medicinal cannabis prescriptions has now concluded.

Trump

Trump Executive Order Signals Major Shift in US Medical Cannabis Policy

Schedule III classification would recognise cannabis as having accepted medical use and lower abuse potential than Schedule I or II substances.

medical cannabis

New York Study Links Medical Cannabis to Reduced Opioid Use

The 22% reduction in opioid use may seem modest, but researchers emphasise this aligns with current clinical recommendations for gradual opioid tapering over extended periods rather than rapid cessation.

hemp

Australia's Hemp Trials Reveal Hard Truths: Industry at Critical Crossroads

The most alarming finding from the trials is the catastrophic variability in imported seed quality.

hyperspectral

Early Leaf Scans Could Revolutionise Cannabis Production

The implications for Australia's emerging cannabis industry are substantial.

Sativex

CNX Therapeutics Acquires Sativex in Strategic CNS Portfolio Expansion

Sativex represents the first plant-derived cannabinoid medicine approved by a medicines regulator, a distinction that underscores its pioneering role in legitimising cannabis-based therapeutics.

OPINION

The Cannabis Paradox: How Australia's Medical Market Boom Became a Domestic Industry Crisis

The industry's 38 tonnes of unsold inventory isn't just an economic problem. It's karma.

Cann Group

Cann Group Secures Major Debt Restructure and $9M Capital Raise

The debt forgiveness of $54.7 million represents an 81% reduction in the company's debt and will increase Cann Group's net assets by approximately $60 million.

tga

From Prohibition to Home Grows: Lessons from Germany's Cannabis Act for Australia's Medical Cannabis Crisis

The contrast between Germany's success and Australia's stagnation raises a fundamental question: what structural differences enable one country to achieve rapid market transformation while another remains locked in gatekeeping and corporate control?

tga

The High Cost of Relief: How Medical Cannabis Pricing Leaves Patients Behind

As health bodies call for crackdown on rogue operators, affordability crisis goes unaddressed.

tga

A Guide for Medicinal Cannabis Users on Completing the TGA Unapproved Product Survey

The Reviewing the Safety and Regulatory Oversight of Unapproved Medicinal Cannabis Products consultation commenced on 11 August 2025 and will close on 7 October.

Ecofibre Limited (ASX: EOF) delisted from the ASX

Ecofibre Limited was an Australian biotechnology company focused on hemp-derived products and technologies. The company listed on the ASX on March 29, 2019, through an IPO that raised $20 million at $1 per share, giving it a market capitalization of $309 million on listing¹. The business was headed by

human rights

The Home Cultivation Gap: Comparing Medical Cannabis Access Rights in Australia and Canada

The prohibition creates a two-tiered system where access depends on wealth. Canadian patients can grow unlimited plants based on prescription. Low-income patients aren't excluded due to cost barriers.